LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

AZN

73.74

+0.19%↑

Search

Novo Nordisk A-S

Fechado

SetorSaúde

55.6 -0.82

Visão Geral

Variação de preço das ações

24h

Atual

Mín

55.36

Máximo

55.62

Indicadores-chave

By Trading Economics

Rendimento

-2.5B

27B

Vendas

-1.2B

77B

P/E

Médio do Setor

15.409

35.69

EPS

6.53

Rendimento de Dividendos

2.84

Margem de lucro

34.484

Funcionários

78,387

EBITDA

-2.5B

44B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+7.79% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.84%

3.08%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

52B

268B

Abertura anterior

56.42

Fecho anterior

55.6

Sentimento de Notícias

By Acuity

74%

26%

341 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Novo Nordisk A-S Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de ago. de 2025, 13:52 UTC

Grandes Movimentos do Mercado

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

18 de ago. de 2025, 09:23 UTC

Grandes Movimentos do Mercado

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

18 de ago. de 2025, 09:23 UTC

Grandes Movimentos do Mercado

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

6 de ago. de 2025, 06:52 UTC

Ganhos

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

6 de ago. de 2025, 06:21 UTC

Ganhos

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

22 de set. de 2025, 13:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18 de set. de 2025, 12:30 UTC

Conversa de Mercado

Correction to Novo Nordisk Market Talk

18 de set. de 2025, 12:00 UTC

Conversa de Mercado

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18 de set. de 2025, 08:55 UTC

Ações em Alta

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

11 de set. de 2025, 10:59 UTC

Conversa de Mercado

Novo Nordisk Investors Cheer Plans to Slim Organization -- Market Talk

10 de set. de 2025, 13:24 UTC

Ganhos

Ozempic Maker Novo Nordisk to Cut 9,000 Jobs -- Update

10 de set. de 2025, 09:16 UTC

Ações em Alta

Stocks to Watch Wednesday: Oracle, GameStop, Novo Nordisk -- WSJ

2 de set. de 2025, 09:14 UTC

Ações em Alta

Stocks to Watch Tuesday: Nestlé, Novo Nordisk, Nvidia -- WSJ

21 de ago. de 2025, 08:49 UTC

Ganhos
Ações em Alta

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

18 de ago. de 2025, 09:23 UTC

Ações em Alta

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

8 de ago. de 2025, 05:32 UTC

Conversa de Mercado

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 de ago. de 2025, 11:32 UTC

Ganhos

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 de ago. de 2025, 11:03 UTC

Ganhos

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 de ago. de 2025, 10:41 UTC

Ganhos

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 de ago. de 2025, 20:34 UTC

Ganhos

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 de ago. de 2025, 08:45 UTC

Ganhos

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

6 de ago. de 2025, 07:19 UTC

Conversa de Mercado
Ganhos

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

6 de ago. de 2025, 05:50 UTC

Ganhos

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

6 de ago. de 2025, 05:48 UTC

Ganhos

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

6 de ago. de 2025, 05:46 UTC

Ganhos

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

6 de ago. de 2025, 05:38 UTC

Ganhos

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

6 de ago. de 2025, 05:37 UTC

Ganhos

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

6 de ago. de 2025, 05:36 UTC

Ganhos

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

6 de ago. de 2025, 05:35 UTC

Ganhos

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

6 de ago. de 2025, 05:34 UTC

Ganhos

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

Comparação entre Pares

Variação de preço

Novo Nordisk A-S Previsão

Preço-alvo

By TipRanks

7.79% parte superior

Previsão para 12 meses

Média 59.94 USD  7.79%

Máximo 70 USD

Mínimo 50 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Novo Nordisk A-S - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

8 ratings

5

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

62.63 / 69.23Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

341 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat